tetano
Editor, Senior Moderator
Sci Rep
. 2022 Apr 20;12(1):6496.
doi: 10.1038/s41598-022-10230-y.
Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination
Eric S Geanes[SUP] 1 [/SUP], Cas LeMaster[SUP] 1 [/SUP], Elizabeth R Fraley[SUP] 1 [/SUP], Santosh Khanal[SUP] 1 [/SUP], Rebecca McLennan[SUP] 1 [/SUP], Elin Grundberg[SUP] 1 2 3 4 [/SUP], Rangaraj Selvarangan[SUP] 2 5 [/SUP], Todd Bradley[SUP] 6 7 8 9 [/SUP]
Affiliations
Abstract
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has resulted in millions of deaths worldwide. Novel coronavirus infections in humans have steadily become more common. Understanding antibody responses to SARS-CoV-2, and identifying conserved, cross-reactive epitopes among coronavirus strains could inform the design of vaccines and therapeutics with broad application. Here, we determined that individuals with previous SARS-CoV-2 infection or vaccinated with the Pfizer-BioNTech BNT162b2 vaccine produced antibody responses that cross-reacted with related betacoronaviruses. Moreover, we designed a peptide-conjugate vaccine with a conserved SARS-CoV-2 S2 spike epitope, immunized mice and determined cross-reactive antibody binding to SARS-CoV-2 and other related coronaviruses. This conserved spike epitope also shared sequence homology to proteins in commensal gut microbiota and could prime immune responses in humans. Thus, SARS-CoV-2 conserved epitopes elicit cross-reactive immune responses to both related coronaviruses and host bacteria that could serve as future targets for broad coronavirus therapeutics and vaccines.
. 2022 Apr 20;12(1):6496.
doi: 10.1038/s41598-022-10230-y.
Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination
Eric S Geanes[SUP] 1 [/SUP], Cas LeMaster[SUP] 1 [/SUP], Elizabeth R Fraley[SUP] 1 [/SUP], Santosh Khanal[SUP] 1 [/SUP], Rebecca McLennan[SUP] 1 [/SUP], Elin Grundberg[SUP] 1 2 3 4 [/SUP], Rangaraj Selvarangan[SUP] 2 5 [/SUP], Todd Bradley[SUP] 6 7 8 9 [/SUP]
Affiliations
- PMID: 35444221
- DOI: 10.1038/s41598-022-10230-y
Abstract
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has resulted in millions of deaths worldwide. Novel coronavirus infections in humans have steadily become more common. Understanding antibody responses to SARS-CoV-2, and identifying conserved, cross-reactive epitopes among coronavirus strains could inform the design of vaccines and therapeutics with broad application. Here, we determined that individuals with previous SARS-CoV-2 infection or vaccinated with the Pfizer-BioNTech BNT162b2 vaccine produced antibody responses that cross-reacted with related betacoronaviruses. Moreover, we designed a peptide-conjugate vaccine with a conserved SARS-CoV-2 S2 spike epitope, immunized mice and determined cross-reactive antibody binding to SARS-CoV-2 and other related coronaviruses. This conserved spike epitope also shared sequence homology to proteins in commensal gut microbiota and could prime immune responses in humans. Thus, SARS-CoV-2 conserved epitopes elicit cross-reactive immune responses to both related coronaviruses and host bacteria that could serve as future targets for broad coronavirus therapeutics and vaccines.